Chemotherapy News and Research

Latest Chemotherapy News and Research

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

The maximal standardized uptake value (called SUVmax) measured from FDG PET readings taken from the primary tumor in head and neck squamous cell carcinoma patients before treatment is a strong predictor of disease-specific survival, overall survival and disease-free survival, while pretreatment SUVmax for lymphodenopathy is strongly associated with distant metastasis, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

1 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

Brain cancer awareness: 55-year-old cycles across USA

Anne Feeley, a 55-year-old mother and brain cancer survivor, will cycle across the country this spring to raise awareness and money for brain cancer research and support.

27 Feb 2010

Kidney Cancer Canada: Survival, support, understanding, research and hope

Survival. Support. Understanding. Research. Hope. These are five words that mean a great deal to Kidney Cancer Canada as National Kidney Month kicks off this March.

27 Feb 2010

ONA: Cutting 300,000 hours of RN care per year may affect quality of patient care

Ontario Nurses' Association President Linda Haslam-Stroud, RN is expressing deep concerns about the quality of patient care at The Ottawa Hospital following word that the facility is cutting approximately 300,000 hours of RN care per year.

27 Feb 2010

MLL cancer cells rely on normal protein to proliferate

Researchers have found that one particularly aggressive type of blood cancer, mixed lineage leukemia (MLL), has an unusual way to keep the molecular motors running. The cancer cells rely on the normal version of an associated protein to stay alive.

27 Feb 2010

Gene signature may help identify risk of colon cancer recurrence

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

26 Feb 2010

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Head and neck cancer patients receiving induction chemotherapy followed by radiation to preserve their larynx have a low-risk of severe voice disability and almost half experienced no eating or swallowing problems, according to a first of its kind study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Integrative oncology program aims to address cancer patients' needs from every angle

The very instant Penny Kukovec was diagnosed with breast cancer her world permanently changed. Suddenly, it felt as if her life was out of her control. She felt powerless and overwhelmed. There were so many unanswered questions.

26 Feb 2010

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

Huixin He, associate professor, nanoscale chemistry at Rutgers University, Newark, and Tamara Minko, professor at the Rutgers Ernest Mario School of Pharmacy, have developed a nanotechnology approach that potentially could eliminate the problems of side effects and drug resistance in the treatment of cancer. Under traditional chemotherapy, cancer cells, like bacteria, can develop resistance to drug therapy, leading to a relapse of the disease.

26 Feb 2010

CPF to partner with ATS to fund Pulmonary Fibrosis research

The Coalition for Pulmonary Fibrosis and the American Thoracic Society, the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced that the CPF will again partner with the ATS to fund Pulmonary Fibrosis (PF) research.

26 Feb 2010

NCCN Guidelines: Chemosensitivity/resistance assays to be part of Principles of Chemotherapy section

Precision Therapeutics announced today that The National Comprehensive Cancer Network® recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section.

26 Feb 2010

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Manhattan Scientifics Inc., a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy.

25 Feb 2010

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.

25 Feb 2010

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells.

25 Feb 2010

Ovarian transplant: A viable method for fertility treatment

For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.

25 Feb 2010

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Wright State University Boonshoft School of Medicine and Miami Valley Hospital announced today the formation of the Wright State University & Premier Health Partners Neuroscience Institute to speed the transfer of research discoveries from bench to bedside, improving the diagnosis and treatment of neurological disorders such as stroke. Ohio Governor Ted Strickland and Chancellor of the Ohio Board of Regents Eric Fingerhut joined Wright State University and Miami Valley Hospital officials in making the announcement.

25 Feb 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Brain cancer awareness: 55-year-old cycles across USA

Kidney Cancer Canada: Survival, support, understanding, research and hope

ONA: Cutting 300,000 hours of RN care per year may affect quality of patient care

MLL cancer cells rely on normal protein to proliferate

Gene signature may help identify risk of colon cancer recurrence

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Integrative oncology program aims to address cancer patients' needs from every angle

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

CPF to partner with ATS to fund Pulmonary Fibrosis research

NCCN Guidelines: Chemosensitivity/resistance assays to be part of Principles of Chemotherapy section

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Genta initiates new dose-ranging study of tesetaxel drug

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

Ovarian transplant: A viable method for fertility treatment

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Cancer Research - Second Edition eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in